These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 2093544)

  • 21. L-Carnitine effects on anemia in uremic rats treated with erythropoietin.
    Azzadin A; Wollny T; Pawlak R; Malyszko JS; Malyszko J; Myśliwiec M; Buczko W
    Nephron; 1999; 83(4):370-1. PubMed ID: 10575305
    [No Abstract]   [Full Text] [Related]  

  • 22. Does anemia correction by rHuEPO improve uremic cardiopathy?
    Carletti P; Bibiano L; Boggi R; Taruscia D; Mioli V
    Kidney Int Suppl; 1993 Jun; 41():S70-1. PubMed ID: 8320949
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Resistance to erythropoietin.
    Lacombe C
    N Engl J Med; 1996 Mar; 334(10):660-2. PubMed ID: 8592534
    [No Abstract]   [Full Text] [Related]  

  • 24. Subcutaneous low doses of recombinant human erythropoietin in predialysis patients do not interfere with the progression of renal failure.
    Savica V; Costantino G; Monardo P; Bellinghieri G
    Am J Nephrol; 1995; 15(1):10-4. PubMed ID: 7872358
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Erythropoietin for zidovudine-induced anemia.
    N Engl J Med; 1990 Oct; 323(15):1069-70. PubMed ID: 2215568
    [No Abstract]   [Full Text] [Related]  

  • 26. Effect of serum parathyroid hormone and aluminum levels on the response to erythropoietin in uremia.
    Ifudu O; Homel P
    Nephron; 1998 Aug; 79(4):477-8. PubMed ID: 9689168
    [No Abstract]   [Full Text] [Related]  

  • 27. Improvement in the haemostatic defect of uraemia after treatment with recombinant human erythropoietin.
    Moia M; Mannucci PM; Vizzotto L; Casati S; Cattaneo M; Ponticelli C
    Lancet; 1987 Nov; 2(8570):1227-9. PubMed ID: 2890852
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment with recombinant human erythropoietin in patients with aluminum overload and hyperparathyroidism.
    Grützmacher P; Ehmer B; Limbach J; Messinger D; Kulbe KD; Scigalla P
    Blood Purif; 1990; 8(5):279-84. PubMed ID: 2091687
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Aluminium intoxication in the rat induces partial resistance to the effect of recombinant human erythropoietin.
    Losekann A; Ureña P; Khiraoui F; Casadevall N; Zins B; Bererhi L; Zingraff J; Bourdon R; Drüeke T
    Nephrol Dial Transplant; 1990; 5(4):258-63. PubMed ID: 2113221
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Recombinant erythropoietin for zidovudine-induced anemia in AIDS.
    Kuehl AK; Noormohamed SE
    Ann Pharmacother; 1995; 29(7-8):778-9. PubMed ID: 8520096
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [The treatment of renal anemia].
    Koch KM
    Verh Dtsch Ges Inn Med; 1989; 95():246-8. PubMed ID: 2603482
    [No Abstract]   [Full Text] [Related]  

  • 32. [The use of erythropoietin in HIV myelodysplasias. Preliminary study].
    Fruttaldo L; Gatti G; Deambrogio V; Mongiò F; Schettino G; Cavagnolo G
    Minerva Med; 1993 Mar; 84(3):103-5. PubMed ID: 8492960
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Effect of deferoxamine on erythropoiesis in patients hemodialyzed for chronic renal insufficiency treated with erythropoietin].
    Kalinowski M; Popławski A; Kaliszewski Z; Juzwiuk J
    Pol Merkur Lekarski; 1996 Oct; 1(4):232-4. PubMed ID: 9156931
    [TBL] [Abstract][Full Text] [Related]  

  • 34. New pharmacoeconomic option in uremic anemia management.
    Savica V; Mantovani L; Santoro D; Ricciardi B; Bellinghieri G
    Clin Nephrol; 2007 Mar; 67(3):200. PubMed ID: 17390747
    [No Abstract]   [Full Text] [Related]  

  • 35. Effect of erythropoietin administration in uremia.
    Gurland HJ; Samtleben W; Schmidt B
    Contrib Nephrol; 1989; 70():172-7. PubMed ID: 2670428
    [No Abstract]   [Full Text] [Related]  

  • 36. Effects of the evening i.v. administration of erythropoietin in haemodialyzed patients.
    Buemi M; Allegra A; Laganà A; Aloisi C; Privitera M; Morabito N; Frisina N
    Riv Eur Sci Med Farmacol; 1993; 15(5-6):195-7. PubMed ID: 7761669
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Chemotherapy-induced anemia.
    Miller CB
    Contrib Nephrol; 1991; 88():248-51; discussion 252-3. PubMed ID: 2040186
    [No Abstract]   [Full Text] [Related]  

  • 38. Resistance to recombinant human erythropoietin therapy: a real clinical entity?
    Stivelman JC
    Semin Nephrol; 1989 Mar; 9(1 Suppl 2):8-11. PubMed ID: 2669085
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Recombinant human erythropoietin and high flux haemodiafiltration.
    Lippi A; Rindi P; Baronti R; Caprioli R; Favilla G; Palmarini D; Cioni L
    Nephrol Dial Transplant; 1995; 10 Suppl 6():51-4. PubMed ID: 8524496
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Influence of recombinant human erythropoietin on growth hormone responses to growth hormone releasing hormone in uremic patients.
    Díez JJ; Iglesias P; Selgas R
    Clin Nephrol; 1994 Feb; 41(2):119. PubMed ID: 8004829
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.